Prescient Therapeutics Ltd has released a press release.
Improved manufacturing route for PTX-100
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- Appendix 4E and 2018 Annual Report
- PTX-200 AML Study Expanded
- June 2018 Appendix 4C - Quarterly
- US Patent Granted for PTX-200 for Ovarian Cancer Treatment
- March 2018 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- Change of Registry Address: Automic P/L - Sydney Office
- Pipeline Collaboration for Next Generation Formulations
- September 2018 Appendix 4C - Quarterly
- Interim Durability Analysis of PTX-200 Breast Cancer Study
- December 2018 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics